Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 34410311.
- Also identified by DOI 10.1001/jamaophthalmol.2021.3192 and PMC identifier 8377606.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study determines which of 8 doses of bevacizumab are effective in treating severe retinopathy of prematurity to carry forward to a large-scale randomized clinical trial.
Medical subject headings
- Retinopathy of Prematurity